Biogen Can't Escape Amended Antitrust Suit Over MS Drug
By Dorothy Atkins · January 28, 2026, 10:39 PM EST
Biogen Inc. must face health plans' claims that it bribed pharmacy benefit managers to stifle generics competition for its multiple sclerosis drug Tecfidera, after an Illinois federal judge found Wednesday that...
To view the full article, register now.